A Phase 3 interventional study of Pemetrexed and Cisplatin in Non Small Cell Lung Cancer, sponsored by Eli Lilly and Company. Completed at 133 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-06-28.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung — 21 open to participants now, 32 under way, 11 of them phase 3. Pemetrexed · Carcinoma, Non-Small-Cell Lung.
Among the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, this one is the 14th largest by enrollment of the 223 interventional ones that give a count, is one of 14 that started in 2008, is one of 44 in phase 3, and was the 70th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →21 of the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Belgium, Brazil and 17 more countries
Ages 18+
Guangzhou Medical University · Sites in China
Ages 18–75
Second Affiliated Hospital of Nanchang University · Sites in China
Ages 18–85
Shanghai Chest Hospital · Sites in China
Ages 18+
Taipei Veterans General Hospital, Taiwan · Sites in Taiwan
Ages 20+
By country, each count listing its studies:
Pemetrexed: first FDA approval 2004 (ALIMTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
227 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 39 · Phase 2 148 · Phase 3 47 · Phase 4 8
First in 2001; this study’s year is marked. 14 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 598 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 64 across the 223 interventional studies. Of the 161 that completed or were terminated, 89 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
76 of 227 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company: 6 open now, 20 under way, 6 of them phase 3. Of 121 finished, 81 (67%) have results posted.
Among the 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company, this one is the 15th largest by enrollment of the 139 interventional ones that give a count, is one of 6 that started in 2008, is one of 25 in phase 3, and was the 61st registered.
Eli Lilly and Company’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
7 of the studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04585490Phase 3Stanford UniversityAdaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC | 2026-12 |
| NCT06417814Phase 3AstraZenecaA Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 2027-01-11 |
| NCT03178552Phase 3Hoffmann-La RocheA Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) | 2027-06-30 |
| NCT05805631Taipei Veterans General Hospital, TaiwanIntrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC | 2026-12-31 |
| NCT06440954Hunan Province Tumor HospitalEfficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases | 2026-12-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among Eli Lilly and Company’s 147 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
This study will compare the overall survival of participants with locally-advanced, Stage III Non-Small Cell Lung Cancer (NSCLC) with nonsquamous cell histology.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants were treated with Pemetrexed plus Cisplatin and concurrent thoracic radiation therapy (TRT) ("Concurrent Phase") for three 21-day cycles, followed by a 3-5 week "Recovery Period," then treated with consolidation chemotherapy with pemetrexed ("Consolidation Phase") for up to four 21-day cycles Concurrent Phase: Pemetrexed: 500 milligrams per meter squared (mg/m\^2), intravenous (IV) on Day 1 of each 21-day cycle for 3 cycles. Cisplatin: 75 mg/m\^2, IV on Day 1 of each 21-day cycle x 3 cycles. TRT: Beginning on Day 1 of chemotherapy, once daily fractions (2 Gray \[Gy\] per day), 5 days a week for 6 weeks and 3 days to target 66 Gy in 33 fractions. Consolidation Phase: Pemetrexed: 500 mg/m\^2, IV on Day 1 of each 21-day cycle up to 4 cycles
Drug: Pemetrexed · Drug: Cisplatin · Radiation: Thoracic Radiation Therapy (TRT)
Participants were treated with Etoposide plus Cisplatin and concurrent TRT ("Concurrent Phase") for two 28-day cycles, followed by a 3-5 week "Recovery Period," then received consolidation treatment with cytotoxic chemotherapy of choice ("Consolidation Phase") for up to 2 cycles Concurrent Phase: Etoposide/Cisplatin (28-day cycle); Etoposide: 50 mg/m\^2, IV on Days 1 to 5 and Days 29 to 33 and Cisplatin: 50 mg/m\^2, IV on Days1, 8, 29, and 36 Consolidation Phase options: Option 1: Continue the same treatment plan as Concurrent Phase Option 2: Vinorelbine/Cisplatin (21-day cycle); Vinorelbine: 30 mg/m\^2, IV on Days 1, 8, 22, and 29; Cisplatin: 75 mg/m\^2, IV on Days 1 and 22 Option 3: Paclitaxel/Carboplatin (21-day cycle); Paclitaxel: 200 mg/m\^2, IV, on Days 1 and 22; Carboplatin: area under the concentration-time curve (AUC) = 6 (Carboplatin dosing based on calculated creatinine clearance), IV on Days 1 and 22
Drug: Cisplatin · Drug: Etoposide · Drug: Vinorelbine · Drug: Paclitaxel · Drug: Carboplatin · Radiation: Thoracic Radiation Therapy (TRT)
infusion over 10 minutes
Also known as: Alimta, LY231514
infusion over 60 minutes with adequate anti-emetic treatment and appropriate hydration per local practice guidelines
administered per local practice guidelines over a minimum of 30 minutes
administered over 6-10 minutes infusion per local practice guidelines
administered as a 3-hour infusion
administered per local practice guidelines over 30 minutes
Overall Survival
Overall survival (OS) time is from baseline to the date of death from any cause. For participants not known to have died as of the data cut-off date, OS time was censored at the last contact date the participant was known to be alive prior to the data cut-off date. OS was summarized using Kaplan-Meier estimates.
Time frame: Baseline to Date of Death from Any Cause (Up to 71.4 Months)
Progression-free Survival (PFS)
Progression-free survival (PFS) time is from baseline to the first date of documented objective progressive disease (PD) or death from any cause. For participants who were not known to have died or to have had objective PD as of the data inclusion cut-off date for a particular analysis, PFS was censored at the date of the last objective progression-free disease assessments. For participants who took any subsequent systemic anticancer therapy prior to progression or death, PFS was censored at the date of the last objective progression-free disease assessment prior to the start date of any subsequent systemic anticancer therapy. PFS time was summarized using Kaplan-Meier estimates.
Time frame: Baseline to Measured Progressive Disease or Death from Any Cause (Up to 66.6 Months)
Objective Response Rate (Complete Response [CR] + Partial Response [PR])
Overall response rate (ORR) is the best response of CR or PR as classified by the investigators according to the Response Evaluation Criteria in Solid Tumors (RECIST, v1.1) guidelines. CR is defined as the disappearance of all target and non-target lesions, normalization of tumor marker level of non-target lesions, and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimeter (mm). PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions. Overall response rate is calculated as a total number of participants with CR or PR divided by the total number of participants with at least 1 measurable lesion, multiplied by 100.
Time frame: Baseline to Measured Progressive Disease (Up to 7 Months)
Survival Rates at 1, 2, and 3 Years
The probability that survival time is at least 1, 2, or 3 years was summarized using Kaplan-Meier estimates.
Time frame: Baseline to Date of Death from Any Cause (Up to 71.4 Months)
First Site of Disease Failure in Terms of Relapse
The percentage of participants with first sites of disease failure in terms of relapse within the radiation treatment field, inside the thorax, (outside of the radiation field), or distant disease are presented. Results were summarized using Kaplan-Meier estimates. Some participants relapsed in more than 1 location/site and appear in more than a single category.
Time frame: Baseline to Relapse (Up to 66.6 Months)
Percentage of Participants With a Post Baseline Swallowing Diary Score >=4
Participants were provided with a swallowing diary to record issues with swallowing using a 5-point categorical scale: (1) no problems; (2) mild soreness; (3) swallowing solids with some difficulty; (4) inability to swallow solids; and (5) inability to swallow liquids. Participants rated swallowing over the previous 24 hours. The percentage of participants was calculated by dividing the number of with a post baseline swallowing diary score \>=4 by total number of participants analyzed, multiplied by 100. No adjustments were made for the number of available assessments nor were any interpolation of missing assessments made.
Time frame: Baseline through 30 Days Post Study
Adverse Events: The Number of Deaths Per Treatment Group
The number of deaths that occurred while on study drug, the number of deaths due to adverse events (AEs) while on study drug, and the number of deaths due to the study disease (that is, disease progression) while on study drug are presented. In addition, the number of deaths within 30 days of treatment discontinuation, the number of deaths due to AEs within 30 days of treatment discontinuation, and the number of deaths due to study disease within 30 days of treatment discontinuation are presented. For both the deaths due to AEs that occurred on study and for deaths due to AEs that occurred within 30 days of treatment discontinuation, the causality (events assess as possibly related \[poss related\] to study drug per investigator judgement) is also presented. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
Time frame: Baseline through 30 Days Post Study
| Milestone | Arm A: Pemetrexed + Cisplatin and TRT | Arm B: Etoposide + Cisplatin and TRT |
|---|---|---|
| Started | 301 | 297 |
| Received at least one dose of study drug | 283 | 272 |
| Entered consolidation phase | 229 | 202 |
| Completed | 177 | 180 |
| Not completed | 124 | 117 |
| Withdrew: Participants censored (no death events) | 124 | 117 |
Overall survival (OS) time is from baseline to the date of death from any cause. For participants not known to have died as of the data cut-off date, OS time was censored at the last contact date the participant was known to be alive prior to the data cut-off date. OS was summarized using Kaplan-Meier estimates.
| months | Arm A: Pemetrexed + Cisplatin and TRT | Arm B: Etoposide + Cisplatin and TRT |
|---|---|---|
| Overall Survival | 26.81 (20.40 to 30.92) | 24.97 (22.18 to 29.83) |
Progression-free survival (PFS) time is from baseline to the first date of documented objective progressive disease (PD) or death from any cause. For participants who were not known to have died or to have had objective PD as of the data inclusion cut-off date for a particular analysis, PFS was censored at the date of the last objective progression-free disease assessments. For participants who took any subsequent systemic anticancer therapy prior to progression or death, PFS was censored at the date of the last objective progression-free disease assessment prior to the start date of any subsequent systemic anticancer therapy. PFS time was summarized using Kaplan-Meier estimates.
| months | Arm A: Pemetrexed + Cisplatin and TRT | Arm B: Etoposide + Cisplatin and TRT |
|---|---|---|
| Progression-free Survival (PFS) | 11.37 (10.25 to 13.21) | 9.76 (8.38 to 11.73) |
Overall response rate (ORR) is the best response of CR or PR as classified by the investigators according to the Response Evaluation Criteria in Solid Tumors (RECIST, v1.1) guidelines. CR is defined as the disappearance of all target and non-target lesions, normalization of tumor marker level of non-target lesions, and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimeter (mm). PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions. Overall response rate is calculated as a total number of participants with CR or PR divided by the total number of participants with at least 1 measurable lesion, multiplied by 100.
| percentage of participants | Arm A: Pemetrexed + Cisplatin and TRT | Arm B: Etoposide + Cisplatin and TRT |
|---|---|---|
| Objective Response Rate (Complete Response [CR] + Partial Response [PR]) | 35.9 (30.46 to 41.58) | 33.0 (27.67 to 38.66) |
The number of deaths that occurred while on study drug, the number of deaths due to adverse events (AEs) while on study drug, and the number of deaths due to the study disease (that is, disease progression) while on study drug are presented. In addition, the number of deaths within 30 days of treatment discontinuation, the number of deaths due to AEs within 30 days of treatment discontinuation, and the number of deaths due to study disease within 30 days of treatment discontinuation are presented. For both the deaths due to AEs that occurred on study and for deaths due to AEs that occurred within 30 days of treatment discontinuation, the causality (events assess as possibly related \[poss related\] to study drug per investigator judgement) is also presented. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
| participants | Arm A: Pemetrexed + Cisplatin and TRT | Arm B: Etoposide + Cisplatin and TRT |
|---|---|---|
| On study drug (total) | 12 | 6 |
| On study drug: Due to AE | 10 | 4 |
| On study drug: Due to AE poss related | 5 | 3 |
| On study drug: Due to study disease | 2 | 0 |
| Within 30 Days of Discontinuation (disc) (total) | 10 | 6 |
| Within 30 Days of Disc: Due to AE | 5 | 4 |
| Within 30 Days of Disc: Due to AE poss related | 2 | 0 |
| Within 30 Days of Disc: Due to study disease | 5 | 2 |
The probability that survival time is at least 1, 2, or 3 years was summarized using Kaplan-Meier estimates.
| probability of survival | Arm A: Pemetrexed + Cisplatin and TRT | Arm B: Etoposide + Cisplatin and TRT |
|---|---|---|
| 1 year (12 months) | 0.76 (0.70 to 0.80) | 0.77 (0.72 to 0.81) |
| 2 years (24 months) | 0.52 (0.46 to 0.58) | 0.52 (0.46 to 0.58) |
| 3 years (36 months) | 0.40 (0.34 to 0.46) | 0.37 (0.31 to 0.43) |
The percentage of participants with first sites of disease failure in terms of relapse within the radiation treatment field, inside the thorax, (outside of the radiation field), or distant disease are presented. Results were summarized using Kaplan-Meier estimates. Some participants relapsed in more than 1 location/site and appear in more than a single category.
| percentage of participants | Arm A: Pemetrexed + Cisplatin and TRT | Arm B: Etoposide + Cisplatin and TRT |
|---|---|---|
| Relapsed within the radiation treatment field | 37.3 (30.0 to 45.2) | 45.8 (38.6 to 53.2) |
| Relapsed inside thorax, outside of radiation field | 20.5 (14.6 to 27.4) | 16.3 (11.4 to 22.4) |
| Relapsed distant disease | 50.0 (42.2 to 57.8) | 45.8 (38.6 to 53.2) |
Participants were provided with a swallowing diary to record issues with swallowing using a 5-point categorical scale: (1) no problems; (2) mild soreness; (3) swallowing solids with some difficulty; (4) inability to swallow solids; and (5) inability to swallow liquids. Participants rated swallowing over the previous 24 hours. The percentage of participants was calculated by dividing the number of with a post baseline swallowing diary score \>=4 by total number of participants analyzed, multiplied by 100. No adjustments were made for the number of available assessments nor were any interpolation of missing assessments made.
| percentage of participants | Arm A: Pemetrexed + Cisplatin and TRT | Arm B: Etoposide + Cisplatin and TRT |
|---|---|---|
| Percentage of Participants With a Post Baseline Swallowing Diary Score >=4 | 33.8 (26.7 to 37.5) | 29.0 (21.3 to 31.7) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A: | — | 134/283 (47.3%) | 279/283 (98.6%) |
| Arm B: Etoposide + Cisplatin and TRT | — | 145/272 (53.3%) | 269/272 (98.9%) |
| Event | Arm A: | Arm B: Etoposide + Cisplatin and TRT |
|---|---|---|
| OesophagitisGastrointestinal disorders | 26/283 | 29/272 |
| Febrile neutropeniaBlood and lymphatic system disorders | 12/283 | 24/272 |
| PneumoniaInfections and infestations | 18/283 | 18/272 |
| VomitingGastrointestinal disorders | 14/283 | 8/272 |
| NeutropeniaBlood and lymphatic system disorders | 8/283 | 13/272 |
| Radiation oesophagitisInjury, poisoning and procedural complications | 7/283 | 13/272 |
| PyrexiaGeneral disorders | 11/283 | 4/272 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 3/283 | 10/272 |
| NauseaGastrointestinal disorders | 8/283 | 7/272 |
| Radiation pneumonitisInjury, poisoning and procedural complications | 7/283 | 5/272 |
| Event | Arm A: | Arm B: Etoposide + Cisplatin and TRT |
|---|---|---|
| NauseaGastrointestinal disorders | 175/283 | 144/272 |
| DysphagiaGastrointestinal disorders | 140/283 | 110/272 |
| FatigueGeneral disorders | 139/283 | 131/272 |
| ConstipationGastrointestinal disorders | 112/283 | 129/272 |
| NeutropeniaBlood and lymphatic system disorders | 92/283 | 123/272 |
| OesophagitisGastrointestinal disorders | 119/283 | 99/272 |
| VomitingGastrointestinal disorders | 110/283 | 95/272 |
| AlopeciaSkin and subcutaneous tissue disorders | 24/283 | 103/272 |
| CoughRespiratory, thoracic and mediastinal disorders | 105/283 | 84/272 |
| Decreased appetiteMetabolism and nutrition disorders | 104/283 | 88/272 |
All randomized participants
| Age, Continuous(years) | Arm A: Pemetrexed + Cisplatin and TRT | Arm B: Etoposide + Cisplatin and TRT | Total |
|---|---|---|---|
| Mean | 59.1 ± 9.6 | 58.5 ± 9.4 | 58.8 ± 9.5 |
| Sex: Female, Male(Participants) | Arm A: Pemetrexed + Cisplatin and TRT | Arm B: Etoposide + Cisplatin and TRT | Total |
|---|---|---|---|
| Female | 124 | 119 | 243 |
| Male | 177 | 178 | 355 |
| Race/Ethnicity, Customized(participants) | Arm A: Pemetrexed + Cisplatin and TRT | Arm B: Etoposide + Cisplatin and TRT | Total |
|---|---|---|---|
| African | 15 | 12 | 27 |
| Caucasian | 217 | 204 | 421 |
| East Asian | 54 | 68 | 122 |
| Hispanic | 5 | 4 | 9 |
| Native American | 1 | 1 | 2 |
| West Asian | 6 | 6 | 12 |
| Missing (unknown) | 3 | 2 | 5 |
| Region of Enrollment(participants) | Arm A: Pemetrexed + Cisplatin and TRT | Arm B: Etoposide + Cisplatin and TRT | Total |
|---|---|---|---|
| Argentina | 2 | 1 | 3 |
| United States | 58 | 76 | 134 |
| United Kingdom | 14 | 5 | 19 |
| Portugal | 7 | 11 | 18 |
| Spain | 38 | 27 | 65 |
| India | 14 | 14 | 28 |
| Greece | 13 | 3 | 16 |
| Canada | 16 | 10 | 26 |
| Netherlands | 26 | 20 | 46 |
| Turkey | 3 | 4 | 7 |
| Belgium | 21 | 23 | 44 |
| Ireland | 1 | 0 | 1 |
| China | 27 | 34 | 61 |
| Taiwan | 11 | 14 | 25 |
| Brazil | 7 | 9 | 16 |
| Korea, Republic of | 6 | 5 | 11 |
| Australia | 7 | 10 | 17 |
| France | 13 | 9 | 22 |
| Germany | 15 | 22 | 37 |
| Mexico | 2 | 0 | 2 |
| ECOG performance status(participants) | Arm A: Pemetrexed + Cisplatin and TRT | Arm B: Etoposide + Cisplatin and TRT | Total |
|---|---|---|---|
| 0 | 148 | 145 | 293 |
| 1 | 152 | 149 | 301 |
| Missing | 1 | 3 | 4 |
| Disease stage(participants) | Arm A: Pemetrexed + Cisplatin and TRT | Arm B: Etoposide + Cisplatin and TRT | Total |
|---|---|---|---|
| Stage IIIA | 140 | 142 | 282 |
| Stage IIIB | 161 | 152 | 313 |
| Missing | 0 | 3 | 3 |
| Histology(participants) | Arm A: Pemetrexed + Cisplatin and TRT | Arm B: Etoposide + Cisplatin and TRT | Total |
|---|---|---|---|
| Adenocarcinoma | 226 | 226 | 452 |
| Large cell carcinoma | 16 | 21 | 37 |
| Other | 59 | 48 | 107 |
| Missing | 0 | 2 | 2 |
| Smoking status(participants) | Arm A: Pemetrexed + Cisplatin and TRT | Arm B: Etoposide + Cisplatin and TRT | Total |
|---|---|---|---|
| Never smoked | 50 | 58 | 108 |
| Moderate smoker | 42 | 38 | 80 |
| Heavy smoker | 190 | 183 | 373 |
| Missing | 19 | 18 | 37 |
1 further baseline measures are reported on the registry.
Showing the first 100 of 133 sites across 19 countries. Choose a country and city above to see the rest.
The record gives a start of Sep 2008, a primary completion of Oct 2014 and a completion of Nov 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2015, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pemetrexed
Carcinoma, Non-Small-Cell Lung →